GSK delivered a weak set of results in the quarter, failing to meet analyst expectations in terms of revenues as well as earnings. The company’s R&D pipeline now includes 68 assets in clinical development, almost two-thirds of which target infectious illness and HIV. GSK is also making good headway in improving its growth prospects for 2026 and beyond. In the quarter, they witnessed two U.S. FDA approvals, two advisory committees, and multiple assets proceed through clinical development, including the initiation of Phase II for their oligonucleotide NASH asset, GSK’990. They also began withdrawing bepirovirsen from their Phase III program for the treatment of chronic hepatitis B. Besides that, GSK disclosed encouraging results from its Men ABCWY Phase III study. They also presented promising Phase III data for gepotidacin in treating uncomplicated urinary tract infections at ECCMID. In addition to gepotidacin, they have been involved in company growth. GSK expanded its infectious diseases portfolio with the addition of tebipenem. In March, the company also agreed to in-license Brexafemme and recently went on to acquire BELLUS Health. We give GSK plc a ‘Hold’ rating with a revised target price.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
Want unlimited access to our reports? Purchase our $99 annual subscription!